Publication

Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference

Lee, J., Werth, V. P., Hall, R. P., Eming, R., Fairley, J. A., Fajgenbaum, D. C., Harman, K. E., Jonkman, M. F., Korman, N. J., Ludwig, R. J., Murrell, D. F., Musette, P., Naik, H. B., Sadik, C. D., Yamagami, J., Yale, M. L. & Payne, A. S., 8-Nov-2018, In : Frontiers in Medicine. 5, 5 p., 306.

Research output: Contribution to journalArticleAcademicpeer-review

  • Jinmin Lee
  • Victoria P. Werth
  • Russell P. Hall
  • Ruediger Eming
  • Janet A. Fairley
  • David C. Fajgenbaum
  • Karen E. Harman
  • Marcel F. Jonkman
  • Neil J. Korman
  • Ralf J. Ludwig
  • Dedee F. Murrell
  • Philippe Musette
  • Haley B. Naik
  • Christian D. Sadik
  • Jun Yamagami
  • Marc L. Yale
  • Aimee S. Payne

The 5th Scientific Conference of the International Pemphigus and Pemphigoid Foundation (IPPF), "Pemphigus and Pemphigoid: A New Era of Clinical and Translational Science" was held in Orlando, Florida, on May 15-16,2018. Scientific sessions covered recent, ongoing, and future clinical trials in pemphigus and bullous pemphigoid, disease activity and quality of life instruments, and the IPPF Natural History Study. Furthermore, the meeting provided an opportunity to hear firsthand from patients, investigators, and industry about their experience enrolling for clinical trials.

Original languageEnglish
Article number306
Number of pages5
JournalFrontiers in Medicine
Volume5
Publication statusPublished - 8-Nov-2018

    Keywords

  • rituximab, Btk, FcRn, eotaxin, T-cell, fumarate, leukotriene, doxycycline, EPIDERMOLYSIS-BULLOSA ACQUISITA, DISEASE, TRIAL

Download statistics

No data available

ID: 76476819